# A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)

> **NCT05063162** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **UCB Biopharma SRL** · enrollment: 113 (actual)

## Conditions studied

- Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)

## Interventions

- **DRUG:** Rozanolixizumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05063162
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-02
- **Primary completion:** 2027-05-06
- **Final completion:** 2027-07-01
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05063162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05063162, "A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05063162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*